Our three pioneering divisions allow MGC to be a key player in all significant levels of production in various global locations. It also allows MGC to progress with simultaneous high level research and development, clinical trials around the world and to embrace new emerging verticals in CBD markets.
Founded in 2014 by experts in the Medical Cannabis field with the intention of capitalising on the emerging global Medical Cannabis industry, founders Nativ Segev and Roby Zomer bring a combination of over 10 years in the Medical Cannabis and the BioTech industry. MGC Pharma was created to become a leading BioPharma company based on Medical Cannabis with operations spanning all aspects of the value chain, from cultivation, manufacturing and distribution of products in a global market.
Today, MGC Pharma has operations spanning Europe and Australia. It has cultivated and harvested crops in its growing facilities in the Czech Republic and Slovenia and is manufacturing active pharmaceutical ingredients (APIs) at its European GMP extraction facility. The Company has also developed a CBD cosmetics range that is available for purchase throughout Europe and online via the Company’s eShop www.mgcderma.com
The Botanic Division engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia. We will continue to harvest the product in Slovenia and Czech Republic, and use the raw material at our production facility, as well as provide the product globally.
Our research & development:
The Innovation Division is focused on our medical product pipeline and is our largest division. This division focuses on products that emerge from our supply line. These include neutraceuticals, which will be able to provide the additional needs and requirements that our body demands on a daily basis to improve our immune system, detoxify and enhance wellness.
Additionally, this includes our extracts, at various levels of purity, and with the ability to extract various phytocannabinoids and terpenes to the level of Active Pharmaceutical Ingredient.
The Innovation division is focused on three specific areas of treatment:
MGC Derma produces CBD enhanced cosmetics, DermaPlus dermatological line and private label manufacturing.
MGC Derma is the brand leading the way in utilising this year’s ‘it’ skin care ingredient: cannabis. Before you get the wrong end of the stick… we’re talking about cannabidiol (CBD) a totally non-psychoactive compound derived from the cannabis plant, which shares part of the ‘fingerprint’ of our genetics, allowing the body to instantly recognise it – and utilise it accordingly. It is MGC Derma’s unique, meticulous extraction and purification process that keeps this ‘fingerprint’ intact; the brand uses only the highest quality cannabidiol in this range of pure yet potent serums, masks, toners and cream. Renowned for its healing, sebum-regulating and moisturising capabilities, CBD is particularly adept at addressing eczema, acne and other problematic skin conditions, as well as minimising signs of ageing, hydrating and nourishing.